This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Priebe, G. P.
Right arrow Articles by Goldberg, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Priebe, G. P.
Right arrow Articles by Goldberg, J. B.

 Previous Article  |  Next Article 

Infection and Immunity, March 2002, p. 1507-1517, Vol. 70, No. 3
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.3.1507-1517.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Construction and Characterization of a Live, Attenuated aroA Deletion Mutant of Pseudomonas aeruginosa as a Candidate Intranasal Vaccine

Gregory P. Priebe,1* Mary M. Brinig,2 Kazue Hatano,1 Martha Grout,1 Fadie T. Coleman,1 Gerald B. Pier,1 and Joanna B. Goldberg2

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts,1 Health Sciences Center, University of Virginia, Charlottesville, Virginia2

Received 26 July 2001/ Returned for modification 22 October 2001/ Accepted 12 December 2001

Antibodies to the lipopolysaccharide O antigen of Pseudomonas aeruginosa mediate high-level immunity, but protective epitopes have proven to be poorly immunogenic, while nonprotective or minimally protective O-antigen epitopes often elicit the best immune responses. With the goal of developing a broadly protective P. aeruginosa vaccine, we used a gene replacement system based on the Flp recombinase to construct an unmarked aroA deletion mutant of the P. aeruginosa serogroup O2/O5 strain PAO1. The resultant aroA deletion mutant of PAO1 is designated PAO1{Delta}aroA. The aroA deletion was confirmed by both PCR and failure of the mutant to grow on minimal media lacking aromatic amino acids. When evaluated for safety and immunogenicity in mice, PAO1{Delta}aroA could be applied either intranasally or intraperitoneally at doses up to 5 x 109 CFU per mouse without adverse effects. No dissemination of PAO1{Delta}aroA to blood, liver, or spleen was detected after intranasal application, and histological evidence of pneumonia was minimal. Intranasal immunization of mice and rabbits elicited high titers of immunoglobulin G to whole bacterial cells and to heat-stable bacterial antigens of all seven prototypic P. aeruginosa serogroup O2/O5 strains. The mouse antisera mediated potent phagocytic killing of most of the prototypic serogroup O2/O5 strains, while the rabbit antisera mediated phagocytic killing of several serogroup-heterologous strains in addition to killing all O2/O5 strains. This live, attenuated P. aeruginosa strain PAO1{Delta}aroA appears to be safe for potential use as an intranasal vaccine and elicits high titers of opsonic antibodies against multiple strains of the P. aeruginosa O2/O5 serogroup.

* Corresponding author. Mailing address: Channing Laboratory, 181 Longwood Ave., Boston, MA 02115. Phone: (617) 525-4248. Fax: (617) 525-2510. E-mail: gpriebe{at}rics.bwh.harvard.edu.

Infection and Immunity, March 2002, p. 1507-1517, Vol. 70, No. 3
0019-9567/02/$04.00+0     DOI: 10.1128/IAI.70.3.1507-1517.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Priebe, G. P., Walsh, R. L., Cederroth, T. A., Kamei, A., Coutinho-Sledge, Y. S., Goldberg, J. B., Pier, G. B. (2008). IL-17 Is a Critical Component of Vaccine-Induced Protection against Lung Infection by Lipopolysaccharide-Heterologous Strains of Pseudomonas aeruginosa. J. Immunol. 181: 4965-4975 [Abstract] [Full Text]  
  • Srivastava, A., Casey, H., Johnson, N., Levy, O., Malley, R. (2007). Recombinant Bactericidal/Permeability-Increasing Protein rBPI21 Protects against Pneumococcal Disease. Infect. Immun. 75: 342-349 [Abstract] [Full Text]  
  • Buzzola, F. R., Barbagelata, M. S., Caccuri, R. L., Sordelli, D. O. (2006). Attenuation and Persistence of and Ability To Induce Protective Immunity to a Staphylococcus aureus aroA Mutant in Mice.. Infect. Immun. 74: 3498-3506 [Abstract] [Full Text]  
  • Zaidi, T. S., Priebe, G. P., Pier, G. B. (2006). A Live-Attenuated Pseudomonas aeruginosa Vaccine Elicits Outer Membrane Protein-Specific Active and Passive Protection against Corneal Infection. Infect. Immun. 74: 975-983 [Abstract] [Full Text]  
  • DiGiandomenico, A., Rao, J., Goldberg, J. B. (2004). Oral Vaccination of BALB/c Mice with Salmonella enterica Serovar Typhimurium Expressing Pseudomonas aeruginosa O Antigen Promotes Increased Survival in an Acute Fatal Pneumonia Model. Infect. Immun. 72: 7012-7021 [Abstract] [Full Text]  
  • Priebe, G. P., Dean, C. R., Zaidi, T., Meluleni, G. J., Coleman, F. T., Coutinho, Y. S., Noto, M. J., Urban, T. A., Pier, G. B., Goldberg, J. B. (2004). The galU Gene of Pseudomonas aeruginosa Is Required for Corneal Infection and Efficient Systemic Spread following Pneumonia but Not for Infection Confined to the Lung. Infect. Immun. 72: 4224-4232 [Abstract] [Full Text]  
  • Priebe, G. P., Meluleni, G. J., Coleman, F. T., Goldberg, J. B., Pier, G. B. (2003). Protection against Fatal Pseudomonas aeruginosa Pneumonia in Mice after Nasal Immunization with a Live, Attenuated aroA Deletion Mutant. Infect. Immun. 71: 1453-1461 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»